HCA Healthcare (NYSE:HCA) Releases FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 24.050-25.850 for the period, compared to the consensus estimate of 24.610. The company issued revenue guidance of $72.8 billion-$75.8 billion, compared to the consensus revenue estimate of $74.8 billion.

HCA Healthcare Stock Down 1.1 %

Shares of NYSE:HCA opened at $321.77 on Friday. The company has a market capitalization of $81.50 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.09 and a beta of 1.64. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. HCA Healthcare has a 52-week low of $279.93 and a 52-week high of $417.14. The stock’s fifty day simple moving average is $314.50 and its 200-day simple moving average is $352.84.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period last year, the company earned $5.90 earnings per share. As a group, equities research analysts forecast that HCA Healthcare will post 21.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on HCA shares. Oppenheimer lifted their price objective on shares of HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research report on Monday, October 28th. TD Cowen reduced their target price on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a report on Monday, October 28th. StockNews.com downgraded shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Barclays dropped their price target on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Finally, KeyCorp cut their price objective on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, HCA Healthcare currently has an average rating of “Moderate Buy” and an average target price of $385.27.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This trade represents a 29.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.